Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.79 USD | -3.07% | -5.96% | +7.98% |
Financials (USD)
Sales 2024 * | 24.88M | Sales 2025 * | 32.7M | Capitalization | 232M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | -25M | EV / Sales 2024 * | 9.34 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.1 x |
P/E ratio 2024 * |
-21.1
x | P/E ratio 2025 * |
-9.15
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
Latest transcript on Aldeyra Therapeutics, Inc.
1 day | -3.07% | ||
1 week | -5.96% | ||
Current month | -3.81% | ||
1 month | -3.56% | ||
3 months | +0.53% | ||
6 months | +44.66% | ||
Current year | +7.98% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Brady
CEO | Chief Executive Officer | 52 | 05-08-31 |
Bruce Greenberg
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Caitlin Pazzano
PRN | Corporate Officer/Principal | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 58 | 09-04-30 |
Martin Joyce
BRD | Director/Board Member | 70 | 13-09-30 |
Ben Bronstein
BRD | Director/Board Member | 74 | 10-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 3.79 | -3.07% | 310,510 |
24-05-24 | 3.91 | +3.17% | 260,694 |
24-05-23 | 3.79 | -2.07% | 314,716 |
24-05-22 | 3.87 | -1.78% | 227,886 |
24-05-21 | 3.94 | -2.23% | 285,134 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.98% | 232M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- ALDX Stock